valeant pharmaceuticals inte (VRX) Key Developments
Valeant it has Filed a Complaint with Securities Regulators in Quebec and the U.S
Jul 22 14
Valeant said on July 21, 2014 it has filed a complaint with securities regulators in Quebec and the U.S. over allegedly unfair tactics by Allergan Inc. Valeant said it has contacted both the Autorité des marchés financiers and the U.S. Securities and Exchange Commission regarding Allergan's "apparent attempt to mislead investors and manipulate the market for Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information. Valeant says Allergan falsely stated last Friday in an SEC filing that Valeant's Bausch + Lomb pharmaceutical sales were stagnant or declining, when in fact they grew about 6% in the second quarter. The U.S. prescription pharmaceutical business grew 17% over the year-earlier period, with the lion's share of that growth due to volume increases.
Galderma S.A. to Distribute Valeant Pharmaceuticals International, Inc.'s Products
Jul 10 14
Galderma S.A. announced that it has gained full rights to distribute Restylane(R), Perlane(R), Emervel(R), Sculptra(R) and Dysport(R) from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide. Galderma will pursue to distribute the acquired products through the existing distribution partner. Healthcare practitioners are invited to continue to order products through their current account number and phone numbers. Beginning July 28, 2014 Galderma will have a new branded distribution process. All accounts will automatically receive a new Galderma account number and information on the new ordering process.
Valeant Pharmaceuticals International, Inc. Receives U.S. Food and Drug Administration Clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine
Jun 16 14
Valeant Pharmaceuticals International, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane(R) Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. Restylane Silk is a crystal clear injectable gel composed of hyaluronic acid, a natural substance that already exists in the body. Restylane Silk is non-animal based and free from animal protein. Allergy pretesting is not necessary. Restylan Silk contains 0.3% lidocaine, which was added to reduce the discomfort associated with the treatment. Clinical study was conducted with Restylane(R) Silk to evaluate the safety and effectiveness of injections to enhance lip fullness and to improve the wrinkles around the lips. The study included 221 mostly female subjects and evaluated subjects with light and dark skin. Subjects with very dark skin were not studied. 98% of subjects reported improvement in their lip fullness 14 days after injection and 76% of the subjects still had lip improvement 6 months after their injection. The majority of adverse events were mild in intensity and the most common symptoms were lip swelling, contusion, and lip pain. The incidence of adverse event decreased significantly after the second treatment. Restylane Silk is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients with a history of allergies to gram positive bacterial proteins; patients with bleeding disorders; for implantation in anatomical spaces other than the dermis or submucosal implantation for lip augmentation and should not be used in patients with previous hypersensitivity to local anesthetics of the amide type, such as lidocaine.
Valeant Pharmaceuticals International, Inc. Announces Planned Departure of Ryan Weldon as Executive Vice President and Group Chairman
Jun 14 14
Valeant Pharmaceuticals International, Inc. (Valeant) announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma.
Valeant Pharmaceuticals International, Inc. - Special Call
Jun 13 14
To discuss recent misleading assertions made by Allergan, Inc. and others